Drug intelligence / Profile preview

BMS-986517

Development stage: Phase 2
Lead developer: Bristol Myers Squibb

Overview

BMS-986517 is an investigational drug under clinical development by Bristol Myers Squibb for the treatment of advanced solid tumors. It is being evaluated in a phase 1/2a, open-label, first-in-human trial primarily aimed at establishing safety and tolerability in participants with solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and hormone receptor-positive/HER2-negative breast cancer. The specific mechanism of action, molecular target, and modality have not been publicly disclosed as of September 2025.

Beyond the preview

Go deeper on BMS-986517.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986517.

Explore the full profile